Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & Administrative
Others
Ratios

Tenax Therapeutics (TENX) EPS (Basic) (2016 - 2017)

Tenax Therapeutics' EPS (Basic) history spans 8 years, with the latest figure at -$0.95 for Q4 2017.

  • For Q4 2017, EPS (Basic) rose 96.92% year-over-year to -$0.95; the TTM value through Dec 2017 reached -$6.27, up 80.03%, while the annual FY2025 figure was -$1.34, 16.52% down from the prior year.
  • EPS (Basic) for Q4 2017 was -$0.95 at Tenax Therapeutics, down from -$0.87 in the prior quarter.
  • Across five years, EPS (Basic) topped out at -$0.08 in Q3 2014 and bottomed at -$30.88 in Q4 2016.
  • The 5-year median for EPS (Basic) is -$0.21 (2015), against an average of -$2.3.
  • The largest annual shift saw EPS (Basic) plummeted 2360.0% in 2013 before it skyrocketed 96.92% in 2017.
  • A 5-year view of EPS (Basic) shows it stood at -$1.23 in 2013, then soared by 88.62% to -$0.14 in 2014, then grew by 7.14% to -$0.13 in 2015, then tumbled by 23653.85% to -$30.88 in 2016, then surged by 96.92% to -$0.95 in 2017.
  • Per Business Quant, the three most recent readings for TENX's EPS (Basic) are -$0.95 (Q4 2017), -$0.87 (Q3 2017), and -$2.12 (Q2 2017).